| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 64 | 2024 | 1230 | 10.380 |
Why?
|
| Cytomegalovirus Infections | 42 | 2024 | 462 | 10.360 |
Why?
|
| Respiratory Syncytial Virus Infections | 30 | 2023 | 427 | 9.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 90 | 2023 | 6550 | 9.030 |
Why?
|
| Respiratory Tract Infections | 25 | 2023 | 437 | 8.570 |
Why?
|
| Immunocompromised Host | 36 | 2024 | 698 | 6.390 |
Why?
|
| Transplant Recipients | 27 | 2024 | 324 | 5.630 |
Why?
|
| Cytomegalovirus | 26 | 2024 | 482 | 5.090 |
Why?
|
| Cross Infection | 27 | 2023 | 544 | 4.580 |
Why?
|
| Ribavirin | 13 | 2019 | 178 | 3.730 |
Why?
|
| Virus Diseases | 11 | 2023 | 398 | 3.670 |
Why?
|
| Hematologic Neoplasms | 24 | 2024 | 1870 | 3.350 |
Why?
|
| Paramyxoviridae Infections | 9 | 2021 | 86 | 3.130 |
Why?
|
| Drug Resistance, Viral | 10 | 2024 | 71 | 3.100 |
Why?
|
| Respiratory Syncytial Virus, Human | 8 | 2023 | 211 | 2.420 |
Why?
|
| Neoplasms | 49 | 2023 | 15193 | 2.380 |
Why?
|
| Organophosphonates | 7 | 2020 | 64 | 2.280 |
Why?
|
| Cytosine | 7 | 2020 | 141 | 2.210 |
Why?
|
| Influenza, Human | 12 | 2021 | 925 | 2.150 |
Why?
|
| Anti-Bacterial Agents | 19 | 2022 | 2992 | 2.100 |
Why?
|
| Infection Control | 12 | 2022 | 270 | 2.070 |
Why?
|
| Gram-Positive Bacterial Infections | 8 | 2021 | 157 | 2.000 |
Why?
|
| Respiratory Syncytial Viruses | 6 | 2019 | 171 | 1.970 |
Why?
|
| Bacteremia | 11 | 2016 | 689 | 1.940 |
Why?
|
| Disinfection | 5 | 2020 | 42 | 1.750 |
Why?
|
| Aerosols | 5 | 2013 | 158 | 1.740 |
Why?
|
| Acetates | 8 | 2021 | 105 | 1.720 |
Why?
|
| Virus Activation | 9 | 2019 | 228 | 1.580 |
Why?
|
| Pneumonia, Viral | 9 | 2017 | 715 | 1.560 |
Why?
|
| Cancer Care Facilities | 9 | 2019 | 884 | 1.550 |
Why?
|
| Humans | 210 | 2024 | 261506 | 1.470 |
Why?
|
| Enzyme-Linked Immunospot Assay | 3 | 2019 | 33 | 1.400 |
Why?
|
| Communicable Diseases | 3 | 2023 | 193 | 1.390 |
Why?
|
| DNA Viruses | 2 | 2020 | 48 | 1.380 |
Why?
|
| Vancomycin-Resistant Enterococci | 2 | 2021 | 16 | 1.380 |
Why?
|
| Quinazolines | 8 | 2021 | 923 | 1.240 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 8 | 2019 | 202 | 1.190 |
Why?
|
| Adult | 101 | 2024 | 77950 | 1.180 |
Why?
|
| Aged | 90 | 2022 | 70117 | 1.150 |
Why?
|
| Bacterial Infections | 5 | 2023 | 479 | 1.150 |
Why?
|
| Community-Acquired Infections | 6 | 2021 | 285 | 1.140 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2012 | 308 | 1.080 |
Why?
|
| Middle Aged | 102 | 2023 | 86204 | 1.070 |
Why?
|
| Opportunistic Infections | 7 | 2015 | 223 | 1.070 |
Why?
|
| Ultraviolet Rays | 4 | 2020 | 575 | 1.050 |
Why?
|
| DNA, Viral | 5 | 2019 | 694 | 1.040 |
Why?
|
| Herpesviridae Infections | 3 | 2016 | 175 | 1.030 |
Why?
|
| Vancomycin Resistance | 4 | 2013 | 54 | 1.030 |
Why?
|
| Young Adult | 42 | 2021 | 21445 | 1.010 |
Why?
|
| Leukemia | 8 | 2021 | 1635 | 1.010 |
Why?
|
| Hospitals | 9 | 2023 | 485 | 1.010 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2019 | 426 | 1.000 |
Why?
|
| Enterobacteriaceae | 2 | 2016 | 46 | 1.000 |
Why?
|
| Enterobacteriaceae Infections | 2 | 2016 | 69 | 0.980 |
Why?
|
| Vaccination | 5 | 2023 | 1123 | 0.970 |
Why?
|
| Male | 110 | 2021 | 123000 | 0.950 |
Why?
|
| Retrospective Studies | 57 | 2023 | 37905 | 0.920 |
Why?
|
| Staphylococcal Infections | 8 | 2019 | 672 | 0.910 |
Why?
|
| Daptomycin | 2 | 2021 | 39 | 0.910 |
Why?
|
| Disease Outbreaks | 7 | 2011 | 415 | 0.900 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2015 | 238 | 0.870 |
Why?
|
| Adolescent | 49 | 2021 | 31252 | 0.870 |
Why?
|
| Tuberculosis | 3 | 2019 | 548 | 0.850 |
Why?
|
| Serratia Infections | 3 | 2011 | 15 | 0.850 |
Why?
|
| Incidence | 21 | 2023 | 5673 | 0.850 |
Why?
|
| Serratia marcescens | 3 | 2011 | 21 | 0.850 |
Why?
|
| Female | 106 | 2021 | 141928 | 0.840 |
Why?
|
| Surgical Wound Infection | 4 | 2014 | 450 | 0.810 |
Why?
|
| Hematology | 1 | 2022 | 104 | 0.790 |
Why?
|
| Transplantation, Homologous | 17 | 2022 | 2843 | 0.790 |
Why?
|
| Immune Reconstitution | 1 | 2021 | 22 | 0.790 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2021 | 12 | 0.790 |
Why?
|
| Immune Sera | 1 | 2021 | 146 | 0.780 |
Why?
|
| Immunization, Passive | 2 | 2021 | 172 | 0.780 |
Why?
|
| Herpesvirus 3, Human | 1 | 2021 | 43 | 0.770 |
Why?
|
| Adenoviridae Infections | 3 | 2017 | 125 | 0.760 |
Why?
|
| Mycoses | 9 | 2023 | 386 | 0.760 |
Why?
|
| Herpesvirus 6, Human | 4 | 2008 | 81 | 0.750 |
Why?
|
| Graft vs Host Disease | 16 | 2023 | 2638 | 0.750 |
Why?
|
| Herpes Zoster | 1 | 2021 | 50 | 0.750 |
Why?
|
| Risk Factors | 31 | 2023 | 17523 | 0.740 |
Why?
|
| DNA Virus Infections | 1 | 2020 | 29 | 0.730 |
Why?
|
| Chemoprevention | 2 | 2019 | 241 | 0.720 |
Why?
|
| Adenovirus Infections, Human | 1 | 2020 | 56 | 0.720 |
Why?
|
| Pandemics | 6 | 2023 | 1559 | 0.710 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 242 | 0.710 |
Why?
|
| Vaccines | 2 | 2015 | 389 | 0.710 |
Why?
|
| Adrenal Gland Diseases | 1 | 2020 | 72 | 0.700 |
Why?
|
| Palivizumab | 6 | 2018 | 64 | 0.700 |
Why?
|
| Phage Therapy | 1 | 2019 | 23 | 0.690 |
Why?
|
| Metapneumovirus | 2 | 2017 | 58 | 0.690 |
Why?
|
| Cystitis | 2 | 2021 | 107 | 0.680 |
Why?
|
| Leukopenia | 2 | 2018 | 151 | 0.660 |
Why?
|
| Minocycline | 3 | 2011 | 182 | 0.650 |
Why?
|
| Drugs, Investigational | 1 | 2019 | 135 | 0.620 |
Why?
|
| Acyclovir | 3 | 2018 | 78 | 0.620 |
Why?
|
| Xenon | 3 | 2020 | 19 | 0.600 |
Why?
|
| Ganciclovir | 6 | 2024 | 174 | 0.600 |
Why?
|
| Treatment Outcome | 32 | 2021 | 32848 | 0.590 |
Why?
|
| Stem Cell Transplantation | 9 | 2020 | 1360 | 0.590 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 1209 | 0.590 |
Why?
|
| Drug Resistance, Microbial | 2 | 2014 | 218 | 0.580 |
Why?
|
| Organ Transplantation | 1 | 2019 | 191 | 0.570 |
Why?
|
| Texas | 15 | 2020 | 6311 | 0.570 |
Why?
|
| Operating Rooms | 1 | 2017 | 122 | 0.560 |
Why?
|
| Azabicyclo Compounds | 1 | 2016 | 36 | 0.560 |
Why?
|
| Isoxazoles | 1 | 2016 | 81 | 0.550 |
Why?
|
| Cost of Illness | 1 | 2019 | 498 | 0.550 |
Why?
|
| Bacterial Load | 2 | 2017 | 46 | 0.550 |
Why?
|
| Ceftazidime | 1 | 2016 | 57 | 0.540 |
Why?
|
| Lymphocyte Transfusion | 1 | 2016 | 175 | 0.540 |
Why?
|
| Aged, 80 and over | 30 | 2021 | 29902 | 0.540 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2014 | 158 | 0.530 |
Why?
|
| Antibodies, Viral | 7 | 2021 | 1320 | 0.530 |
Why?
|
| Sodium Hypochlorite | 1 | 2015 | 12 | 0.520 |
Why?
|
| Child, Preschool | 20 | 2023 | 16273 | 0.520 |
Why?
|
| Environmental Microbiology | 1 | 2015 | 22 | 0.510 |
Why?
|
| Equipment Contamination | 3 | 2011 | 90 | 0.510 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2015 | 152 | 0.510 |
Why?
|
| Herbaspirillum | 1 | 2014 | 6 | 0.510 |
Why?
|
| Catheter-Related Infections | 5 | 2019 | 270 | 0.510 |
Why?
|
| beta-Lactamases | 2 | 2016 | 179 | 0.500 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2016 | 87 | 0.500 |
Why?
|
| Pharmacogenetics | 1 | 2016 | 260 | 0.500 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 573 | 0.490 |
Why?
|
| Viral Load | 5 | 2020 | 493 | 0.490 |
Why?
|
| Health Personnel | 3 | 2020 | 625 | 0.490 |
Why?
|
| Aminoglycosides | 2 | 2014 | 220 | 0.480 |
Why?
|
| Administration, Inhalation | 4 | 2019 | 285 | 0.480 |
Why?
|
| Drug Contamination | 2 | 2011 | 52 | 0.480 |
Why?
|
| Clinical Trials as Topic | 7 | 2023 | 3719 | 0.480 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2015 | 1303 | 0.480 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 2403 | 0.480 |
Why?
|
| Syringes | 3 | 2011 | 42 | 0.470 |
Why?
|
| Drug Resistance, Multiple | 1 | 2014 | 204 | 0.470 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 111 | 0.460 |
Why?
|
| beta-Lactams | 1 | 2013 | 53 | 0.460 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2018 | 254 | 0.450 |
Why?
|
| Influenza Vaccines | 2 | 2016 | 635 | 0.440 |
Why?
|
| Anti-Infective Agents | 4 | 2019 | 446 | 0.430 |
Why?
|
| Genotype | 5 | 2016 | 4109 | 0.430 |
Why?
|
| Ribonucleosides | 3 | 2024 | 40 | 0.430 |
Why?
|
| Child | 25 | 2023 | 29154 | 0.420 |
Why?
|
| Environmental Restoration and Remediation | 1 | 2011 | 3 | 0.420 |
Why?
|
| Abdominal Neoplasms | 1 | 2013 | 231 | 0.400 |
Why?
|
| Herpes Simplex | 3 | 2018 | 95 | 0.400 |
Why?
|
| BK Virus | 3 | 2020 | 123 | 0.400 |
Why?
|
| Furunculosis | 1 | 2011 | 8 | 0.400 |
Why?
|
| Vancomycin | 2 | 2016 | 273 | 0.400 |
Why?
|
| Patients' Rooms | 1 | 2011 | 11 | 0.400 |
Why?
|
| United States | 17 | 2023 | 15433 | 0.400 |
Why?
|
| T-Lymphocytes | 5 | 2022 | 3869 | 0.400 |
Why?
|
| Transplantation Conditioning | 7 | 2018 | 2238 | 0.400 |
Why?
|
| Immunocompetence | 2 | 2010 | 75 | 0.390 |
Why?
|
| Disease Transmission, Infectious | 2 | 2011 | 94 | 0.390 |
Why?
|
| Immunity, Cellular | 4 | 2021 | 419 | 0.380 |
Why?
|
| Prospective Studies | 11 | 2024 | 12873 | 0.370 |
Why?
|
| Catheters, Indwelling | 2 | 2011 | 374 | 0.370 |
Why?
|
| Lung Transplantation | 2 | 2005 | 359 | 0.370 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 324 | 0.360 |
Why?
|
| Viral Fusion Proteins | 3 | 2020 | 85 | 0.360 |
Why?
|
| Valine | 1 | 2010 | 176 | 0.360 |
Why?
|
| Oseltamivir | 2 | 2021 | 33 | 0.350 |
Why?
|
| Clostridium Infections | 3 | 2022 | 252 | 0.350 |
Why?
|
| Pneumonia | 4 | 2024 | 751 | 0.350 |
Why?
|
| Rifampin | 2 | 2011 | 191 | 0.350 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 120 | 0.350 |
Why?
|
| Cause of Death | 2 | 2017 | 752 | 0.340 |
Why?
|
| Transplantation, Haploidentical | 2 | 2021 | 125 | 0.330 |
Why?
|
| Cell- and Tissue-Based Therapy | 5 | 2022 | 406 | 0.330 |
Why?
|
| Lymphoma | 2 | 2009 | 1467 | 0.330 |
Why?
|
| Antigens, Viral | 3 | 2020 | 471 | 0.330 |
Why?
|
| Enterococcus | 3 | 2015 | 59 | 0.330 |
Why?
|
| Lymphopenia | 2 | 2023 | 199 | 0.330 |
Why?
|
| Simplexvirus | 1 | 2009 | 159 | 0.320 |
Why?
|
| Catheterization, Central Venous | 4 | 2011 | 354 | 0.320 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2021 | 994 | 0.310 |
Why?
|
| Cohort Studies | 11 | 2021 | 9244 | 0.310 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 3001 | 0.310 |
Why?
|
| Polyomavirus Infections | 2 | 2020 | 139 | 0.300 |
Why?
|
| Dichlororibofuranosylbenzimidazole | 2 | 2024 | 12 | 0.300 |
Why?
|
| Gram-Negative Bacteria | 2 | 2008 | 100 | 0.300 |
Why?
|
| Pseudomonas Infections | 3 | 2019 | 156 | 0.300 |
Why?
|
| Tumor Virus Infections | 2 | 2020 | 224 | 0.300 |
Why?
|
| Infant | 9 | 2021 | 13310 | 0.300 |
Why?
|
| Viremia | 3 | 2022 | 177 | 0.300 |
Why?
|
| Neuraminidase | 1 | 2007 | 69 | 0.300 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2024 | 3251 | 0.290 |
Why?
|
| Antifungal Agents | 7 | 2018 | 834 | 0.280 |
Why?
|
| Critical Care | 2 | 2011 | 770 | 0.280 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2020 | 544 | 0.270 |
Why?
|
| Aspergillosis | 1 | 2008 | 246 | 0.270 |
Why?
|
| Postoperative Complications | 4 | 2019 | 5542 | 0.270 |
Why?
|
| Patient Isolation | 2 | 2018 | 25 | 0.270 |
Why?
|
| Double-Blind Method | 7 | 2020 | 2588 | 0.260 |
Why?
|
| Lung | 3 | 2021 | 3151 | 0.250 |
Why?
|
| Risk Assessment | 10 | 2020 | 6869 | 0.250 |
Why?
|
| Recurrence | 6 | 2023 | 4758 | 0.240 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 4298 | 0.240 |
Why?
|
| Endocarditis | 2 | 2006 | 125 | 0.240 |
Why?
|
| Logistic Models | 6 | 2019 | 3441 | 0.240 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2023 | 53 | 0.240 |
Why?
|
| Immunity, Humoral | 2 | 2021 | 86 | 0.240 |
Why?
|
| Phenazines | 1 | 2003 | 13 | 0.240 |
Why?
|
| Gentian Violet | 1 | 2003 | 20 | 0.240 |
Why?
|
| Leukemia, Myeloid, Acute | 6 | 2022 | 6915 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2009 | 1039 | 0.230 |
Why?
|
| Allografts | 4 | 2021 | 650 | 0.230 |
Why?
|
| Liver Abscess | 1 | 2003 | 36 | 0.230 |
Why?
|
| Thiazoles | 1 | 2007 | 726 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 4 | 2018 | 4367 | 0.230 |
Why?
|
| Interferon-gamma | 2 | 2019 | 1144 | 0.230 |
Why?
|
| Nasopharynx | 1 | 2023 | 119 | 0.230 |
Why?
|
| Gram-Positive Bacteria | 1 | 2003 | 66 | 0.230 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 4320 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2005 | 362 | 0.220 |
Why?
|
| Stethoscopes | 1 | 2022 | 8 | 0.220 |
Why?
|
| Hand Hygiene | 1 | 2022 | 14 | 0.220 |
Why?
|
| Hand Disinfection | 2 | 2022 | 19 | 0.220 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2021 | 1555 | 0.220 |
Why?
|
| Antibodies, Neutralizing | 4 | 2021 | 541 | 0.220 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2016 | 180 | 0.220 |
Why?
|
| Candidiasis | 2 | 2002 | 262 | 0.220 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 672 | 0.210 |
Why?
|
| Epiglottis | 1 | 2002 | 12 | 0.210 |
Why?
|
| Survival Rate | 9 | 2021 | 12221 | 0.210 |
Why?
|
| Dibenzothiepins | 1 | 2021 | 6 | 0.210 |
Why?
|
| Leukemia, Myeloid | 1 | 2007 | 941 | 0.210 |
Why?
|
| Neutropenia | 5 | 2018 | 968 | 0.210 |
Why?
|
| Zygomycosis | 1 | 2002 | 31 | 0.210 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 2315 | 0.200 |
Why?
|
| Tongue | 1 | 2002 | 77 | 0.200 |
Why?
|
| Roseolovirus Infections | 1 | 2002 | 39 | 0.200 |
Why?
|
| Histoplasma | 1 | 2001 | 32 | 0.200 |
Why?
|
| Foscarnet | 2 | 2022 | 17 | 0.200 |
Why?
|
| Infectious Mononucleosis | 1 | 2001 | 33 | 0.200 |
Why?
|
| Mutation | 3 | 2024 | 15179 | 0.200 |
Why?
|
| Viral Structural Proteins | 1 | 2021 | 47 | 0.200 |
Why?
|
| DNA Probes | 1 | 2001 | 217 | 0.200 |
Why?
|
| Zika Virus | 1 | 2023 | 144 | 0.200 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2021 | 29 | 0.200 |
Why?
|
| Drug Combinations | 3 | 2016 | 621 | 0.200 |
Why?
|
| Histoplasmosis | 1 | 2001 | 74 | 0.200 |
Why?
|
| Hemorrhagic Disorders | 1 | 2021 | 51 | 0.190 |
Why?
|
| Immunity, Mucosal | 1 | 2021 | 108 | 0.190 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2024 | 129 | 0.190 |
Why?
|
| Triazines | 1 | 2021 | 117 | 0.190 |
Why?
|
| Zika Virus Infection | 1 | 2023 | 166 | 0.190 |
Why?
|
| Rotavirus Infections | 1 | 2003 | 287 | 0.190 |
Why?
|
| Gastroenteritis | 1 | 2003 | 300 | 0.190 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 4 | 2014 | 128 | 0.190 |
Why?
|
| Gastrointestinal Diseases | 1 | 2005 | 589 | 0.190 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 1375 | 0.190 |
Why?
|
| Benzimidazoles | 3 | 2024 | 428 | 0.190 |
Why?
|
| Treatment Failure | 3 | 2019 | 1391 | 0.190 |
Why?
|
| Contact Tracing | 1 | 2020 | 56 | 0.180 |
Why?
|
| Morpholines | 1 | 2021 | 289 | 0.180 |
Why?
|
| Administration, Oral | 3 | 2019 | 1544 | 0.180 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2019 | 16 | 0.180 |
Why?
|
| DNA, Ribosomal | 2 | 2014 | 103 | 0.170 |
Why?
|
| Intensive Care Units | 4 | 2019 | 717 | 0.170 |
Why?
|
| Measles | 1 | 2019 | 36 | 0.170 |
Why?
|
| Phylogeny | 1 | 2021 | 826 | 0.170 |
Why?
|
| HLA-DP Antigens | 1 | 2019 | 21 | 0.170 |
Why?
|
| Acinetobacter Infections | 1 | 2019 | 28 | 0.170 |
Why?
|
| Pyridones | 1 | 2021 | 348 | 0.170 |
Why?
|
| Catheterization | 2 | 2014 | 410 | 0.170 |
Why?
|
| Urinary Tract Infections | 2 | 2019 | 321 | 0.170 |
Why?
|
| Klebsiella Infections | 1 | 2019 | 64 | 0.170 |
Why?
|
| Histocompatibility Testing | 2 | 2019 | 447 | 0.170 |
Why?
|
| Food Safety | 1 | 2018 | 7 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2021 | 6207 | 0.160 |
Why?
|
| Biomarkers | 3 | 2019 | 5047 | 0.160 |
Why?
|
| Rubulavirus | 1 | 2018 | 8 | 0.160 |
Why?
|
| Respiratory Mucosa | 1 | 2020 | 206 | 0.160 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 207 | 0.160 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2015 | 362 | 0.160 |
Why?
|
| Venous Thrombosis | 1 | 2002 | 384 | 0.160 |
Why?
|
| Serologic Tests | 1 | 2018 | 137 | 0.160 |
Why?
|
| Bone Marrow Transplantation | 2 | 2020 | 1581 | 0.160 |
Why?
|
| Survival Analysis | 5 | 2017 | 9180 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 3203 | 0.160 |
Why?
|
| Medical Records | 1 | 2019 | 415 | 0.150 |
Why?
|
| Acids, Carbocyclic | 1 | 2017 | 3 | 0.150 |
Why?
|
| Hypoxia | 2 | 2017 | 443 | 0.150 |
Why?
|
| Disease Management | 2 | 2020 | 1052 | 0.150 |
Why?
|
| Zanamivir | 1 | 2017 | 8 | 0.150 |
Why?
|
| Staphylococcus lugdunensis | 1 | 2016 | 1 | 0.150 |
Why?
|
| Viruses | 1 | 2018 | 159 | 0.150 |
Why?
|
| China | 2 | 2016 | 606 | 0.150 |
Why?
|
| Amantadine | 1 | 2017 | 33 | 0.150 |
Why?
|
| Drug Resistance, Multiple, Viral | 2 | 2014 | 9 | 0.150 |
Why?
|
| HIV Infections | 3 | 2016 | 2134 | 0.150 |
Why?
|
| Feces | 2 | 2015 | 770 | 0.150 |
Why?
|
| Time Factors | 10 | 2020 | 12926 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2016 | 907 | 0.150 |
Why?
|
| Guanidines | 1 | 2017 | 60 | 0.150 |
Why?
|
| Heart Valve Prosthesis | 1 | 2001 | 386 | 0.150 |
Why?
|
| Cyclopentanes | 1 | 2017 | 40 | 0.150 |
Why?
|
| Colony Count, Microbial | 2 | 2015 | 149 | 0.150 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 11538 | 0.150 |
Why?
|
| Tissue Donors | 2 | 2023 | 769 | 0.150 |
Why?
|
| Antimicrobial Stewardship | 1 | 2018 | 84 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2018 | 441 | 0.140 |
Why?
|
| Picornaviridae Infections | 1 | 2017 | 57 | 0.140 |
Why?
|
| Aspergillus | 2 | 2008 | 149 | 0.140 |
Why?
|
| Terminology as Topic | 1 | 2019 | 414 | 0.140 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2016 | 44 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2015 | 430 | 0.140 |
Why?
|
| DNA, Bacterial | 3 | 2014 | 558 | 0.140 |
Why?
|
| Urologic Diseases | 1 | 2016 | 78 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2020 | 649 | 0.140 |
Why?
|
| Sputum | 1 | 2016 | 141 | 0.140 |
Why?
|
| Myeloablative Agonists | 2 | 2016 | 384 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2018 | 574 | 0.140 |
Why?
|
| Mucor | 1 | 2015 | 18 | 0.140 |
Why?
|
| Cluster Analysis | 3 | 2014 | 1053 | 0.140 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2008 | 233 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2016 | 490 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2007 | 2527 | 0.140 |
Why?
|
| Transplantation | 2 | 2013 | 56 | 0.140 |
Why?
|
| Genome, Fungal | 1 | 2015 | 54 | 0.140 |
Why?
|
| Length of Stay | 3 | 2019 | 1900 | 0.140 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 1016 | 0.130 |
Why?
|
| Infant, Newborn | 3 | 2021 | 8223 | 0.130 |
Why?
|
| Case-Control Studies | 5 | 2010 | 6100 | 0.130 |
Why?
|
| Placebos | 2 | 2020 | 437 | 0.130 |
Why?
|
| Administration, Intravesical | 1 | 2015 | 162 | 0.130 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2016 | 182 | 0.130 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 486 | 0.130 |
Why?
|
| Hospitalization | 3 | 2019 | 2083 | 0.130 |
Why?
|
| Bronchoscopy | 1 | 2018 | 474 | 0.130 |
Why?
|
| Prevalence | 3 | 2019 | 3260 | 0.130 |
Why?
|
| Immunization Schedule | 1 | 2015 | 117 | 0.130 |
Why?
|
| Pyrimidines | 1 | 2007 | 3518 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2017 | 2316 | 0.130 |
Why?
|
| Betaproteobacteria | 1 | 2014 | 6 | 0.130 |
Why?
|
| Burkholderia cepacia | 1 | 2014 | 7 | 0.130 |
Why?
|
| Fungi | 3 | 2008 | 145 | 0.130 |
Why?
|
| Microbial Viability | 1 | 2015 | 62 | 0.130 |
Why?
|
| Interferons | 1 | 2016 | 291 | 0.130 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 4744 | 0.130 |
Why?
|
| Bacteria | 1 | 2019 | 611 | 0.130 |
Why?
|
| Plasma | 1 | 2015 | 158 | 0.130 |
Why?
|
| Mortality | 1 | 2017 | 343 | 0.120 |
Why?
|
| Staphylococcus aureus | 3 | 2008 | 548 | 0.120 |
Why?
|
| Prognosis | 7 | 2016 | 21713 | 0.120 |
Why?
|
| Molecular Typing | 1 | 2014 | 55 | 0.120 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2022 | 2979 | 0.120 |
Why?
|
| Leukocidins | 2 | 2011 | 46 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 333 | 0.120 |
Why?
|
| Mucormycosis | 1 | 2015 | 108 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 755 | 0.120 |
Why?
|
| Antilymphocyte Serum | 1 | 2015 | 228 | 0.120 |
Why?
|
| Europe | 3 | 2023 | 649 | 0.120 |
Why?
|
| Blood | 1 | 2014 | 156 | 0.120 |
Why?
|
| Exotoxins | 2 | 2011 | 77 | 0.120 |
Why?
|
| Ambulatory Care | 1 | 2018 | 554 | 0.120 |
Why?
|
| Animals | 7 | 2022 | 59536 | 0.120 |
Why?
|
| Interleukins | 1 | 2016 | 325 | 0.120 |
Why?
|
| Viral Proteins | 1 | 2016 | 435 | 0.120 |
Why?
|
| Amphotericin B | 2 | 2007 | 289 | 0.120 |
Why?
|
| Sodium Chloride | 2 | 2011 | 156 | 0.120 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 98 | 0.110 |
Why?
|
| Immunization | 1 | 2015 | 397 | 0.110 |
Why?
|
| Calcineurin Inhibitors | 2 | 2023 | 68 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2016 | 418 | 0.110 |
Why?
|
| Follow-Up Studies | 7 | 2015 | 14889 | 0.110 |
Why?
|
| Sepsis | 2 | 2009 | 652 | 0.110 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 669 | 0.110 |
Why?
|
| Bacterial Toxins | 2 | 2011 | 228 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 2 | 2024 | 2483 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 4892 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2019 | 851 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 4757 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 317 | 0.100 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 181 | 0.100 |
Why?
|
| Data Collection | 1 | 2014 | 620 | 0.100 |
Why?
|
| United States Food and Drug Administration | 2 | 2010 | 332 | 0.100 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 289 | 0.100 |
Why?
|
| Heparin | 2 | 2011 | 360 | 0.100 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 4988 | 0.100 |
Why?
|
| Respiration, Artificial | 2 | 2019 | 577 | 0.100 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2011 | 16 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 350 | 0.100 |
Why?
|
| Vomiting | 2 | 2009 | 354 | 0.090 |
Why?
|
| Nephritis, Interstitial | 1 | 2011 | 76 | 0.090 |
Why?
|
| Diet | 1 | 2018 | 1440 | 0.090 |
Why?
|
| Nausea | 2 | 2009 | 525 | 0.090 |
Why?
|
| Alleles | 1 | 2016 | 2437 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2012 | 329 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2016 | 2218 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2013 | 451 | 0.090 |
Why?
|
| Drug Approval | 1 | 2010 | 178 | 0.090 |
Why?
|
| Parainfluenza Virus 2, Human | 1 | 2008 | 4 | 0.090 |
Why?
|
| Disease Progression | 3 | 2019 | 6682 | 0.090 |
Why?
|
| Epiglottitis | 1 | 2008 | 16 | 0.080 |
Why?
|
| Regression Analysis | 2 | 2010 | 1546 | 0.080 |
Why?
|
| Virus Shedding | 2 | 2020 | 88 | 0.080 |
Why?
|
| Croup | 1 | 2008 | 15 | 0.080 |
Why?
|
| Mannans | 1 | 2008 | 31 | 0.080 |
Why?
|
| beta-Glucans | 1 | 2008 | 34 | 0.080 |
Why?
|
| Coronavirus Infections | 1 | 2017 | 651 | 0.080 |
Why?
|
| Fungemia | 2 | 2015 | 116 | 0.080 |
Why?
|
| Mastectomy, Segmental | 1 | 2014 | 1026 | 0.080 |
Why?
|
| Equipment and Supplies | 1 | 2008 | 48 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2016 | 3890 | 0.080 |
Why?
|
| Vitamin B 6 | 1 | 2008 | 19 | 0.080 |
Why?
|
| Sex Factors | 2 | 2021 | 2139 | 0.080 |
Why?
|
| Probability | 2 | 2007 | 866 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 130 | 0.080 |
Why?
|
| Parvovirus B19, Human | 1 | 2007 | 39 | 0.080 |
Why?
|
| Parvoviridae Infections | 1 | 2007 | 38 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2016 | 2054 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2016 | 1589 | 0.080 |
Why?
|
| Phosphatidylglycerols | 1 | 2007 | 33 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2016 | 2086 | 0.080 |
Why?
|
| Stomatitis, Herpetic | 1 | 2007 | 7 | 0.080 |
Why?
|
| Ventilation | 1 | 2007 | 20 | 0.080 |
Why?
|
| Bacterial Adhesion | 1 | 2008 | 147 | 0.080 |
Why?
|
| Environment, Controlled | 1 | 2007 | 21 | 0.080 |
Why?
|
| Oxazolidinones | 1 | 2008 | 60 | 0.080 |
Why?
|
| Multiple Myeloma | 1 | 1999 | 2138 | 0.080 |
Why?
|
| Enterococcus faecalis | 1 | 2007 | 49 | 0.080 |
Why?
|
| Enterococcus faecium | 1 | 2007 | 46 | 0.080 |
Why?
|
| Adenoviridae | 1 | 2013 | 1459 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2014 | 977 | 0.080 |
Why?
|
| Endophthalmitis | 1 | 2008 | 84 | 0.080 |
Why?
|
| Granulocytes | 1 | 2008 | 224 | 0.070 |
Why?
|
| Phosphatidylcholines | 1 | 2007 | 144 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2012 | 451 | 0.070 |
Why?
|
| Colistin | 1 | 2007 | 33 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 4938 | 0.070 |
Why?
|
| Acetamides | 1 | 2008 | 113 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 739 | 0.070 |
Why?
|
| Escherichia coli Infections | 1 | 2009 | 241 | 0.070 |
Why?
|
| Carbapenems | 2 | 2022 | 62 | 0.070 |
Why?
|
| Herpesvirus 1, Human | 1 | 2007 | 113 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2021 | 1021 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2014 | 929 | 0.070 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 242 | 0.070 |
Why?
|
| Pneumocystis carinii | 1 | 2006 | 20 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2021 | 4971 | 0.070 |
Why?
|
| Interleukin-2 | 1 | 2009 | 842 | 0.070 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2006 | 68 | 0.070 |
Why?
|
| Empyema | 1 | 2006 | 28 | 0.070 |
Why?
|
| Joint Diseases | 1 | 2006 | 71 | 0.070 |
Why?
|
| APACHE | 1 | 2005 | 93 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 147 | 0.070 |
Why?
|
| Chest Tubes | 1 | 2006 | 101 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2023 | 2358 | 0.060 |
Why?
|
| Candida | 2 | 2008 | 164 | 0.060 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2006 | 121 | 0.060 |
Why?
|
| HLA Antigens | 2 | 2021 | 546 | 0.060 |
Why?
|
| Endocarditis, Bacterial | 1 | 2006 | 128 | 0.060 |
Why?
|
| DNA Fingerprinting | 3 | 2009 | 167 | 0.060 |
Why?
|
| Bacterial Typing Techniques | 3 | 2009 | 139 | 0.060 |
Why?
|
| Histological Techniques | 1 | 2004 | 65 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2008 | 583 | 0.060 |
Why?
|
| Dasatinib | 1 | 2007 | 862 | 0.060 |
Why?
|
| Rituximab | 2 | 2024 | 1528 | 0.060 |
Why?
|
| Age Factors | 2 | 2021 | 5377 | 0.060 |
Why?
|
| Diarrhea, Infantile | 1 | 2003 | 43 | 0.060 |
Why?
|
| DNA | 2 | 2024 | 2693 | 0.060 |
Why?
|
| Pasteurella Infections | 1 | 2003 | 9 | 0.060 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 82 | 0.060 |
Why?
|
| Pasteurella multocida | 1 | 2003 | 12 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 15862 | 0.060 |
Why?
|
| Xylose | 1 | 2022 | 19 | 0.060 |
Why?
|
| Hygiene | 1 | 2022 | 24 | 0.060 |
Why?
|
| Cats | 1 | 2003 | 166 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2005 | 375 | 0.060 |
Why?
|
| Escherichia coli | 1 | 2009 | 1203 | 0.050 |
Why?
|
| Bacteriological Techniques | 1 | 2003 | 121 | 0.050 |
Why?
|
| Bacteroides | 1 | 2022 | 42 | 0.050 |
Why?
|
| Pulmonary Embolism | 2 | 2006 | 329 | 0.050 |
Why?
|
| Survivorship | 1 | 2023 | 109 | 0.050 |
Why?
|
| Mucus | 1 | 2022 | 119 | 0.050 |
Why?
|
| Laboratories | 1 | 2003 | 145 | 0.050 |
Why?
|
| Tongue Diseases | 1 | 2002 | 17 | 0.050 |
Why?
|
| Societies | 1 | 2021 | 38 | 0.050 |
Why?
|
| Seasons | 1 | 2003 | 340 | 0.050 |
Why?
|
| Candida glabrata | 1 | 2002 | 45 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 13658 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2003 | 299 | 0.050 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2001 | 70 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2022 | 197 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 285 | 0.050 |
Why?
|
| Triazoles | 1 | 2005 | 617 | 0.050 |
Why?
|
| RNA, Ribosomal | 1 | 2001 | 83 | 0.050 |
Why?
|
| Administration, Topical | 2 | 2014 | 257 | 0.050 |
Why?
|
| Equipment Reuse | 1 | 2020 | 11 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2021 | 1819 | 0.050 |
Why?
|
| Acute Disease | 2 | 2019 | 2422 | 0.050 |
Why?
|
| Living Donors | 1 | 2021 | 171 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 237 | 0.050 |
Why?
|
| Rotavirus | 1 | 2003 | 377 | 0.050 |
Why?
|
| Comorbidity | 1 | 2007 | 2352 | 0.050 |
Why?
|
| Immunoassay | 1 | 2021 | 216 | 0.050 |
Why?
|
| Vero Cells | 1 | 2020 | 143 | 0.050 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2020 | 51 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2021 | 383 | 0.050 |
Why?
|
| Antibody Affinity | 1 | 2020 | 61 | 0.050 |
Why?
|
| Respiratory System | 1 | 2020 | 125 | 0.050 |
Why?
|
| Siblings | 1 | 2021 | 285 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 64 | 0.040 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2023 | 621 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2002 | 305 | 0.040 |
Why?
|
| Idarubicin | 1 | 2002 | 446 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 249 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 2019 | 97 | 0.040 |
Why?
|
| Oxygen | 1 | 2023 | 754 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 703 | 0.040 |
Why?
|
| Molecular Epidemiology | 2 | 2009 | 246 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 7548 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2021 | 10001 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2022 | 834 | 0.040 |
Why?
|
| Liver | 1 | 2007 | 2961 | 0.040 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 14289 | 0.040 |
Why?
|
| Mexico | 1 | 2017 | 259 | 0.040 |
Why?
|
| Aortic Valve | 1 | 2001 | 581 | 0.040 |
Why?
|
| Hospitals, University | 2 | 2007 | 209 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2019 | 467 | 0.040 |
Why?
|
| Premedication | 1 | 2017 | 135 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2017 | 257 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2009 | 2390 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.040 |
Why?
|
| Autopsy | 2 | 2007 | 173 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 945 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 980 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 1914 | 0.030 |
Why?
|
| Organizational Policy | 1 | 2016 | 73 | 0.030 |
Why?
|
| Biodiversity | 1 | 2016 | 91 | 0.030 |
Why?
|
| Onychomycosis | 1 | 2015 | 17 | 0.030 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2015 | 31 | 0.030 |
Why?
|
| Coinfection | 1 | 2017 | 189 | 0.030 |
Why?
|
| Metagenomics | 1 | 2016 | 115 | 0.030 |
Why?
|
| Cytarabine | 1 | 2002 | 1973 | 0.030 |
Why?
|
| Age Distribution | 2 | 2007 | 698 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2003 | 1429 | 0.030 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 8865 | 0.030 |
Why?
|
| Metagenome | 1 | 2016 | 176 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2018 | 1258 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2015 | 254 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2014 | 73 | 0.030 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2014 | 20 | 0.030 |
Why?
|
| Radiology | 1 | 2019 | 434 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2014 | 72 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2014 | 61 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 960 | 0.030 |
Why?
|
| Remission Induction | 1 | 2019 | 3569 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 298 | 0.030 |
Why?
|
| Host-Pathogen Interactions | 1 | 2015 | 314 | 0.030 |
Why?
|
| Diarrhea | 1 | 2017 | 686 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 1335 | 0.030 |
Why?
|
| Critical Illness | 2 | 2008 | 714 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2014 | 844 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 227 | 0.030 |
Why?
|
| Causality | 1 | 2012 | 178 | 0.030 |
Why?
|
| Blood-Borne Pathogens | 1 | 2011 | 13 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1972 | 0.020 |
Why?
|
| Canada | 1 | 2011 | 429 | 0.020 |
Why?
|
| Drug and Narcotic Control | 1 | 2009 | 31 | 0.020 |
Why?
|
| Isotonic Solutions | 1 | 2009 | 46 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2012 | 671 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2012 | 864 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 15694 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 904 | 0.020 |
Why?
|
| Hepacivirus | 1 | 2012 | 397 | 0.020 |
Why?
|
| Drug Industry | 1 | 2009 | 88 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 573 | 0.020 |
Why?
|
| Nasal Lavage Fluid | 1 | 2008 | 19 | 0.020 |
Why?
|
| Hoarseness | 1 | 2008 | 25 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 1294 | 0.020 |
Why?
|
| Galactose | 1 | 2008 | 87 | 0.020 |
Why?
|
| Taste Disorders | 1 | 2008 | 17 | 0.020 |
Why?
|
| Quality Control | 1 | 2009 | 457 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 627 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 4233 | 0.020 |
Why?
|
| Linezolid | 1 | 2008 | 64 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 3890 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1323 | 0.020 |
Why?
|
| Hospital Bed Capacity, 300 to 499 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Air Movements | 1 | 2007 | 7 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2008 | 259 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 465 | 0.020 |
Why?
|
| Cough | 1 | 2008 | 116 | 0.020 |
Why?
|
| Air Microbiology | 1 | 2007 | 30 | 0.020 |
Why?
|
| Saliva | 1 | 2008 | 231 | 0.020 |
Why?
|
| Mouthwashes | 1 | 2007 | 41 | 0.020 |
Why?
|
| Filtration | 1 | 2007 | 92 | 0.020 |
Why?
|
| Vitrectomy | 1 | 2008 | 100 | 0.020 |
Why?
|
| Particle Size | 1 | 2007 | 182 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 6089 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2291 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 669 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1165 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2006 | 72 | 0.020 |
Why?
|
| Intracranial Embolism | 1 | 2006 | 39 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2007 | 327 | 0.020 |
Why?
|
| Oncology Service, Hospital | 1 | 2005 | 48 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2007 | 193 | 0.020 |
Why?
|
| Drug Resistance, Fungal | 1 | 2005 | 92 | 0.020 |
Why?
|
| Liposomes | 1 | 2007 | 684 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2006 | 155 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2005 | 495 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2006 | 303 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 3230 | 0.010 |
Why?
|
| Carrier State | 1 | 2003 | 90 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2008 | 1029 | 0.010 |
Why?
|
| Fatigue | 1 | 2008 | 1239 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2012 | 4314 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 2307 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 6009 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 34495 | 0.010 |
Why?
|
| Quality of Life | 1 | 2015 | 4532 | 0.010 |
Why?
|
| Echocardiography | 1 | 2006 | 1182 | 0.010 |
Why?
|
| Heart | 1 | 2006 | 1223 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2006 | 1374 | 0.010 |
Why?
|